Autopsy report · NCT00076726

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis

“Interim analysis, infliximab did not reduce number of first relapses in GCA or cumulative glucocorticosteroid dosage”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 1 year 8 months before it stopped.
• 44 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Centocor, Inc.

Sponsor type

Industry

Conditions

Giant Cell Arteritis

Interventions

Infliximab

Participants

44

Trials that died the same way

• Infliximab Accelerated Induction in Moderate to Severe Pediatric UC
  “Difficulty to recruit patients and as high dose infliximab for severe UC is now the rule rather than the exception” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.